Øyvind Hjertner

2.3k total citations
27 papers, 1.5k citations indexed

About

Øyvind Hjertner is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Øyvind Hjertner has authored 27 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hematology, 15 papers in Molecular Biology and 11 papers in Oncology. Recurrent topics in Øyvind Hjertner's work include Multiple Myeloma Research and Treatments (19 papers), Bone health and treatments (9 papers) and Bone Metabolism and Diseases (8 papers). Øyvind Hjertner is often cited by papers focused on Multiple Myeloma Research and Treatments (19 papers), Bone health and treatments (9 papers) and Bone Metabolism and Diseases (8 papers). Øyvind Hjertner collaborates with scholars based in Norway, Denmark and Sweden. Øyvind Hjertner's co-authors include Magne Børset, Anders Sundan, Anders Waage, Carina Seidel, Henrik Hjorth‐Hansen, Ralph D. Sanderson, Therese Standal, Niels Abildgaard, Gunnar Qvigstad and Ingunn Bakke and has published in prestigious journals such as Blood, Oncogene and Journal of Bone and Mineral Research.

In The Last Decade

Øyvind Hjertner

26 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Øyvind Hjertner Norway 14 785 679 650 152 150 27 1.5k
Gianluigi Castoldi Italy 27 823 1.0× 544 0.8× 830 1.3× 99 0.7× 39 0.3× 91 2.6k
Harumi Y. Mukai Japan 19 246 0.3× 244 0.4× 486 0.7× 80 0.5× 52 0.3× 54 1.1k
Heather Fairfield United States 17 412 0.5× 326 0.5× 327 0.5× 92 0.6× 18 0.1× 44 1.0k
Monika Jansson Sweden 21 683 0.9× 133 0.2× 461 0.7× 199 1.3× 116 0.8× 41 1.5k
Theresa M. Palabrica United States 13 238 0.3× 90 0.1× 544 0.8× 87 0.6× 63 0.4× 17 1.8k
S Bord United Kingdom 25 1.1k 1.4× 642 0.9× 179 0.3× 64 0.4× 11 0.1× 30 2.1k
Thomas H. Ambrosi United States 10 408 0.5× 170 0.3× 194 0.3× 120 0.8× 17 0.1× 22 1.0k
Rita Campanelli Italy 24 764 1.0× 276 0.4× 500 0.8× 59 0.4× 10 0.1× 56 1.8k
Scott T. Avecilla United States 14 515 0.7× 390 0.6× 911 1.4× 54 0.4× 6 0.0× 36 1.6k
E. Michael Meyer United States 13 370 0.5× 208 0.3× 118 0.2× 100 0.7× 18 0.1× 27 1.3k

Countries citing papers authored by Øyvind Hjertner

Since Specialization
Citations

This map shows the geographic impact of Øyvind Hjertner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Øyvind Hjertner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Øyvind Hjertner more than expected).

Fields of papers citing papers by Øyvind Hjertner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Øyvind Hjertner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Øyvind Hjertner. The network helps show where Øyvind Hjertner may publish in the future.

Co-authorship network of co-authors of Øyvind Hjertner

This figure shows the co-authorship network connecting the top 25 collaborators of Øyvind Hjertner. A scholar is included among the top collaborators of Øyvind Hjertner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Øyvind Hjertner. Øyvind Hjertner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Slørdahl, Tobias S., Nils Tore Vethe, Henrik Hjorth‐Hansen, et al.. (2025). Combined Proteasome and Autophagy Inhibition in Relapsed/Refractory Multiple Myeloma—A Phase I Trial of Hydroxychloroquine, Carfilzomib, and Dexamethasone. eJHaem. 6(1). e1091–e1091.
2.
Myklebust, Tor Åge, et al.. (2021). Patterns of previous and secondary malignancies in patients with multiple myeloma. European Journal Of Haematology. 106(4). 529–536. 5 indexed citations
3.
Myklebust, Tor Åge, et al.. (2020). Incidence and survival of multiple myeloma: a population‐based study of 10 524 patients diagnosed 1982–2017. British Journal of Haematology. 191(3). 418–425. 39 indexed citations
4.
Myklebust, Tor Åge, et al.. (2019). Incidence and Survival of Multiple Myeloma; A Population-Based Study on 10 961 Patients Diagnosed 1982-2017. Blood. 134(Supplement_1). 4380–4380. 1 indexed citations
5.
Gimsing, Peter, Øyvind Hjertner, Niels Abildgaard, et al.. (2015). Salvage bortezomib–dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial. Bone Marrow Transplantation. 50(10). 1306–1311. 10 indexed citations
6.
Fossmark, Reidar, et al.. (2013). Serotonin in blood: Assessment of its origin by concomitant determination of β-thromboglobulin (platelets) and chromogranin A (enterochromaffin cells). Scandinavian Journal of Clinical and Laboratory Investigation. 73(2). 148–153. 5 indexed citations
7.
Hjorth, Martin, Øyvind Hjertner, Lene Meldgaard Knudsen, et al.. (2012). Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. European Journal Of Haematology. 88(6). 485–496. 41 indexed citations
8.
9.
Bjelland, Thor Wilhelm, et al.. (2010). Antiplatelet effect of clopidogrel is reduced in patients treated with therapeutic hypothermia after cardiac arrest. Resuscitation. 81(12). 1627–1631. 50 indexed citations
10.
Hjertner, Øyvind, Therese Standal, Magne Børset, Anders Sundan, & Anders Waage. (2006). Bone Disease in Multiple Myeloma. Medical Oncology. 23(4). 431–442. 5 indexed citations
11.
Hjertner, Øyvind, Therese Standal, Magne Børset, Anders Sundan, & Anders Waage. (2005). Identification of New Targets for Therapy of Osteolytic Bone Disease in Multiple Myeloma. Current Drug Targets. 6(6). 701–711. 6 indexed citations
12.
Standal, Therese, Henrik Hjorth‐Hansen, Thomas Rasmussen, et al.. (2004). Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma.. PubMed. 89(2). 174–82. 63 indexed citations
13.
Rø, Torstein B., Randi Utne Holt, Anne‐Tove Brenne, et al.. (2003). Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells. Oncogene. 23(17). 3024–3032. 104 indexed citations
14.
Reseland, Janne E., Unni Syversen, Ingunn Bakke, et al.. (2001). Leptin Is Expressed in and Secreted from Primary Cultures of Human Osteoblasts and Promotes Bone Mineralization. Journal of Bone and Mineral Research. 16(8). 1426–1433. 284 indexed citations
15.
Seidel, Carina, Øyvind Hjertner, Niels Abildgaard, et al.. (2001). Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood. 98(7). 2269–2271. 130 indexed citations
16.
Hjertner, Øyvind, Gunnar Qvigstad, Henrik Hjorth‐Hansen, et al.. (2000). Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells. British Journal of Haematology. 109(4). 815–822. 29 indexed citations
17.
Seidel, Carina, Magne Børset, Øyvind Hjertner, et al.. (2000). High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity. Blood. 96(9). 3139–3146. 88 indexed citations
18.
Børset, Magne, Øyvind Hjertner, Shmuel Yaccoby, Joshua Epstein, & Ralph D. Sanderson. (2000). Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. Blood. 96(7). 2528–2536. 8 indexed citations
19.
Hjertner, Øyvind, Maria Lyngaas Torgersen, Carina Seidel, et al.. (1999). Hepatocyte Growth Factor (HGF) Induces Interleukin-11 Secretion From Osteoblasts: A Possible Role for HGF in Myeloma-Associated Osteolytic Bone Disease. Blood. 94(11). 3883–3888. 89 indexed citations
20.
Hjertner, Øyvind, Magne Børset, & Anders Waage. (1996). Comparison of the effects of 2-chlorodeoxyadenosine and melphalan on myeloma cell lines. Leukemia Research. 20(2). 155–160. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gianluigi Castoldi Breakdown of academic impact, for papers by Harumi Y. Mukai Breakdown of academic impact, for papers by Heather Fairfield Breakdown of academic impact, for papers by Monika Jansson Breakdown of academic impact, for papers by Theresa M. Palabrica Breakdown of academic impact, for papers by S Bord Breakdown of academic impact, for papers by Thomas H. Ambrosi Breakdown of academic impact, for papers by Rita Campanelli Breakdown of academic impact, for papers by Scott T. Avecilla Breakdown of academic impact, for papers by E. Michael Meyer
Rankless by CCL
2026